Pharmacokinetic study and bioavailability of a novel synthetic trioxane antimalarial compound 97/63 in rats

Malaria Research and Treatment

Volumn 2014, Issue , 2014, Pages

  Kushwaha, Hari Narayan ^a   Mohan, Neel Kamal ^a   Sharma, Ashok Kumar ^a   Singh, Shio Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; ANTIMALARIAL AGENT; BUFFER; COMPOUND 97 63; HEXANE; PHOSPHATE BUFFER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NONHUMAN; PHARMACOKINETIC ASSAY; PLASMA CONCENTRATION-TIME CURVE; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; VALIDATION STUDY;

EID: 84990918158     PISSN: 20908075     EISSN: 20444362     Source Type: Journal    
DOI: 10.1155/2014/759392     Document Type: Article

References (24)

1. Q.-G. Li, J. O. Peggins, L. L. Fleckenstein, K. Masonic, M. H. Heiffer, and T. G. Brewer, "The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats," Journal of Pharmacy and Pharmacology, vol. 50, no. 2, pp. 173-182, 1998.
2. Y. Wu, "How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view," Accounts of Chemical Research, vol. 35, no. 5, pp. 255-259, 2002.
3. A. Robert, O. Dechy-Cabaret, J. Cazelles, and B. Meunier, "From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs," Accounts of Chemical Research, vol. 35, no. 3, pp. 167-174, 2002.
4. F. Cheng, J. Shen, X. Luo et al., "Molecular docking and 3-D-QSAR studies on the possible antimalarial mechanism of artemisinin analogues," Bioorganic and Medicinal Chemistry, vol. 10, no. 9, pp. 2883-2891, 2002.
5. C. Singh, H. Malik, and S. K. Puri, "Orally active amino functionalized antimalarial 1, 2, 4-trioxanes," Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 2, pp. 459-462, 2004.
6. C. Singh and S. K. Puri, Indian Patent IN 191710, 2004.
7. C. Singh, N. Gupta, and S.K. Puri, "Photooxygenationof 3-aryl-2-cyclohexenols: synthesis of a new series of antimalarial 1, 2, 4-trioxanes," Tetrahedron Letters, vol. 46, no. 2, pp. 205-207, 2005.
8. A. G. Griesbeck, T. T. El-Idreesy, L.-O. Höinck, J. Lex, and R. Brun, "Novel spiroanellated 1, 2, 4-trioxanes with high in vitro antimalarial activities," Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 3, pp. 595-597, 2005.
9. C. Singh, N. C. Srivastav, and S. K. Puri, "Synthesis and antimalarial activity of 6-cycloalkylvinyl substituted 1, 2, 4-trioxanes," Bioorganic&Medicinal Chemistry, vol. 12, no. 22, pp. 5745-5752, 2004.
10. S.K. Singh, R.P. Singh, and R. C. Gupta, "HPLC-UVmethod for assaying 99/357, a synthetic trioxane antimalarial derivative in rat and rabbit serum," Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 2, pp. 371-376, 2004.
11. J. Rautio, H. Kumpulainen, T. Heimbach et al., "Prodrugs: design and clinical applications," Nature Reviews Drug Discovery, vol. 7, no. 3, pp. 255-270, 2008.
12. N. V. Nagaraja, J. K. Paliwal, and R. C. Gupta, "Choosing the calibration model in assay validation," Journal of Pharmaceutical and Biomedical Analysis, vol. 20, no. 3, pp. 433-438, 1999.
13. V. P. Shah, K. K. Midha, J. W. A. Findlay et al., "Bioanalytical method validation-a revisit with a decade of progress," Pharmaceutical Research, vol. 17, no. 12, pp. 1551-1557, 2000.
14. M. Rajanikanth and R. C. Gupta, "LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing N-in-One dosing," Journal of Pharmaceutical and Biomedical Analysis, vol. 26, no. 4, pp. 519-530, 2001.
15. J. Lal, N. Mehrotra, and R. C. Gupta, "Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method-a pilot study," Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 1, pp. 141-150, 2003.
16. H. B. Waynforth, Experimental and Surgical Technique in the Rat, Academic Press, London, UK, 1980.
17. M. Issar, S. K. Singh, B. Mishra, and R. C. Gupta, "A sensitive LC assay for the simultaneous determination of centbutindole and its metabolite in rat serum using fluorescence detection," Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 1-2, pp. 347-353, 2002.
18. H. Jonathon and H. G. Richard, Transdermal Drug Delivery, Marcel Dekker, Basel, Switzerland, 1989.
19. V. F. Smollen and L. A. Ball, "Controlled Drug Bioavailability, 3. Bioavailability control by drug delivery system design," 1983.
20. V. J. Stella and K.W. Nti-Addae, "Prodrug strategies toovercome poor water solubility," Advanced Drug Delivery Reviews, vol. 59, no. 7, pp. 677-694, 2007.
21. C. E. Müller, "Prodrug approaches for enhancing the bioavailability of drugs with low solubility," Chemistry and Biodiversity, vol. 6, no. 11, pp. 2071-2083, 2009.
22. V. J. Stella, W.N. A. Charman, and V.H. Naringrekar, "Prodrugs. Do they have advantages in clinical practice?" Drugs, vol. 29, no. 5, pp. 455-473, 1985.
23. P. Ettmayer, G. L. Amidon, B. Clement, and B. Testa, "Lessons learned from marketed and investigational prodrugs," Journal of Medicinal Chemistry, vol. 47, no. 10, pp. 2393-2404, 2004.
24. R. P. Singh, S. Sabarinath, N. Gautam, R. C. Gupta, and S. K. Singh, "Pharmacokinetic study of the novel, synthetic trioxane antimalarial compound 97-78 in rats using an LC-MS/MS method for quantification," Arzneimittel-Forschung/Drug Research, vol. 61, no. 2, pp. 120-125, 2011.